Allspring Global Investments Holdings LLC Invests $402,000 in Stoke Therapeutics, Inc. $STOK

Allspring Global Investments Holdings LLC purchased a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 35,404 shares of the company’s stock, valued at approximately $402,000. Allspring Global Investments Holdings LLC owned about 0.06% of Stoke Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock valued at $36,000 after acquiring an additional 5,084 shares during the period. AlphaQuest LLC bought a new stake in Stoke Therapeutics during the first quarter worth approximately $72,000. US Bancorp DE raised its position in shares of Stoke Therapeutics by 9,743.9% during the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after purchasing an additional 11,108 shares during the period. KLP Kapitalforvaltning AS lifted its stake in Stoke Therapeutics by 131.6% during the second quarter. KLP Kapitalforvaltning AS now owns 13,200 shares of the company’s stock valued at $150,000 after buying an additional 7,500 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Stoke Therapeutics in the 1st quarter valued at approximately $92,000.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $32.28 on Friday. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $38.69. The company’s 50 day simple moving average is $24.77 and its 200 day simple moving average is $15.68. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of 37.98 and a beta of 1.24.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.17. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. The company had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $31.51 million. As a group, analysts predict that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. BTIG Research boosted their price objective on shares of Stoke Therapeutics from $28.00 to $39.00 and gave the company a “buy” rating in a research report on Monday, October 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Stoke Therapeutics in a research note on Wednesday, October 8th. Jefferies Financial Group assumed coverage on shares of Stoke Therapeutics in a report on Friday, July 18th. They issued a “buy” rating and a $30.00 price target for the company. Needham & Company LLC lifted their price objective on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Finally, Wedbush lifted their target price on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.83.

Insider Activity at Stoke Therapeutics

In related news, insider Barry Ticho sold 5,501 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total transaction of $109,304.87. Following the completion of the sale, the insider directly owned 18,469 shares in the company, valued at $366,979.03. This represents a 22.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Md Kaye sold 25,000 shares of the company’s stock in a transaction dated Wednesday, October 8th. The stock was sold at an average price of $30.00, for a total value of $750,000.00. Following the completion of the transaction, the director directly owned 49,124 shares of the company’s stock, valued at approximately $1,473,720. The trade was a 33.73% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 185,180 shares of company stock worth $4,129,406. Company insiders own 9.50% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.